Literature DB >> 34120452

Renal Injuries in Primary Aldosteronism: Quantitative Histopathological Analysis of 19 Patients With Primary Adosteronism.

Hiroko Ogata1, Yuto Yamazaki1,2, Yuta Tezuka3,4, Xin Gao1, Kei Omata2,3, Yoshikiyo Ono2,3, Yoshihide Kawasaki5, Tomoaki Tanaka6, Hidekazu Nagano6, Norio Wada7, Yutaka Oki8, Akira Ikeya8, Kenji Oki9, Yoshiyu Takeda10, Mitsuhiro Kometani10, Kazunori Kageyama11, Ken Terui11, Celso E Gomez-Sanchez12,13, Shujun Liu14, Ryo Morimoto3, Kensuke Joh15, Hiroshi Sato16, Mariko Miyazaki3, Akihiro Ito5, Yoichi Arai5, Yasuhiro Nakamura17, Sadayoshi Ito3, Fumitoshi Satoh2,3, Hironobu Sasano1.   

Abstract

[Figure: see text].

Entities:  

Keywords:  11βHSD; aldosterone; histopathology; hypertension; mineralocorticoid receptor; renin

Mesh：

Year:  2021        PMID： 34120452      PMCID： PMC8597934          DOI： 10.1161/HYPERTENSIONAHA.121.17436

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   9.897


  37 in total

1.  Nuclear shuttling precedes dimerization in mineralocorticoid receptor signaling.

Authors:  Claudia Grossmann; Stefanie Ruhs; Lisa Langenbruch; Sigrid Mildenberger; Nicole Strätz; Katja Schumann; Michael Gekle
Journal:  Chem Biol       Date:  2012-06-22

2.  Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia.

Authors:  J S Williams; G H Williams; A Raji; X Jeunemaitre; N J Brown; P N Hopkins; P R Conlin
Journal:  J Hum Hypertens       Date:  2006-02       Impact factor: 3.012

3.  Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Authors:  Yuto Yamazaki; Yasuhiro Nakamura; Kei Omata; Kazue Ise; Yuta Tezuka; Yoshikiyo Ono; Ryo Morimoto; Yukinaga Nozawa; Celso E Gomez-Sanchez; Scott A Tomlins; William E Rainey; Sadayoshi Ito; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

4.  Renal damage in primary aldosteronism: results of the PAPY Study.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Massimo Mannelli; Mee-Jung Matterello; Domenico Montemurro; Gaetana Palumbo; Damiano Rizzoni; Ermanno Rossi; Achille Cesare Pessina; Franco Mantero
Journal:  Hypertension       Date:  2006-06-26       Impact factor: 10.190

5.  Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11β-HSD activity.

Authors:  Andrew S Brem; David J Morris; Yan Ge; Lance Dworkin; Evelyn Tolbert; Rujun Gong
Journal:  Am J Physiol Renal Physiol       Date:  2010-03-03

Review 6.  Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling.

Authors:  Jane A Leopold
Journal:  Circulation       Date:  2011-11-01       Impact factor: 29.690

7.  Renal Resistive Index Predicts Postoperative Blood Pressure Outcome in Primary Aldosteronism.

Authors:  Yoshitsugu Iwakura; Sadayoshi Ito; Ryo Morimoto; Masataka Kudo; Yoshikiyo Ono; Masahiro Nezu; Kei Takase; Kazumasa Seiji; Shigeto Ishidoya; Yoichi Arai; Yasuharu Funamizu; Takashi Miki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Hypertension       Date:  2016-01-25       Impact factor: 10.190

8.  Morphometric and visual evaluation of fibrosis in renal biopsies.

Authors:  Alton B Farris; Catherine D Adams; Nicole Brousaides; Patricia A Della Pelle; A Bernard Collins; Ellie Moradi; R Neal Smith; Paul C Grimm; Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

9.  The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.

Authors:  Daniel Lavall; Christian Selzer; Pia Schuster; Matthias Lenski; Oliver Adam; Hans-Joachim Schäfers; Michael Böhm; Ulrich Laufs
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

10.  The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial.

Authors:  Hitoshi Minakuchi; Shu Wakino; Hidenori Urai; Arata Kurokochi; Kazuhiro Hasegawa; Takeshi Kanda; Hirobumi Tokuyama; Hiroshi Itoh
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379
View more
  4 in total

Review 1.  Impact of Primary Aldosteronism in Resistant Hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Dimitrios Patoulias; Alexandra Katsimardou; Michael Doumas
Journal:  Curr Hypertens Rep       Date:  2022-04-21       Impact factor: 4.592

Review 2.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02

3.  Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Authors:  Chung-Yi Cheng; Hung-Wei Liao; Kang-Yung Peng; Tso-Hsiao Chen; Yen-Hung Lin; Jeff S Chueh; Vin-Cent Wu
Journal:  Biomedicines       Date:  2021-12-02

Review 4.  Cellular Senescence in Adrenocortical Biology and Its Disorders.

Authors:  Xin Gao; Faping Li; Bin Liu; Yuxiong Wang; Yishu Wang; Honglan Zhou
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.